MDXG - Bathi sadurunge bunga, pajak, lan amortisasi MiMedx Group Inc

MiMedx Group, Inc. (MDXG) is scaling the presence of its biomaterials in clinics by expanding its graft product line. Absolute EBITDA reflects current commercial activity, where the parameter value equals 0.00. However, synthetic alternatives and insurance risks are putting pressure on the business. Stability is maintained through strict adherence to raw material procurement ethics and safe waste disposal within ESG standards.

MiMedx Group - Bathi operasional EBITDA MDXG (periode 23.11.2025 - 11.11.2026)

Ringkesan rincian data analitis MiMedx (MDXG)

- kuotasi saiki lan rata-rata prakiraan nilai:

Kutipan saham MiMedx Corp|MDXG - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Nilai pasar MiMedx|MDXG - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Rega Buku Saham MiMedx|MDXG - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku mimedx.com|MDXG - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- rincian asil keuangan lan kelipatan valuasi:

MDXG - Bathi resik perusahaan|Bathi mangsa ngarep MiMedx Group, Inc.|MDXG - Rasio rega marang bathi|Prakiraan rega marang bathi mimedx.com|MDXG - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan MiMedx|MDXG - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan MiMedx|MDXG - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan mimedx.com|MDXG - Wutah bathi ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep MiMedx Group, Inc.

Analisis kabeh metrik perusahaan:MiMedx Corp (MDXG)

Produk sing diprodhuksi MiMedx Group, Inc.

Operational efficiency serves as a key value driver for MiMedx Group, Inc. (MDXG). The company's adjusted EBITDA reflects actual cash flow from core operations by excluding non-cash accounting write-downs. Growth in this metric confirms the returns from the robotization of biomaterial processing lines and the implementation of AI-driven controls. This price action allows for the tracking of profitability between reporting periods; however, peak values necessitate caution to avoid overpaying for the asset.

Karo sapa MiMedx Group, Inc. saingan